Three Bridge Wealth Advisors LLC Purchases 11,107 Shares of Novo Nordisk A/S (NYSE:NVO)

Three Bridge Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 88.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,665 shares of the company's stock after buying an additional 11,107 shares during the period. Three Bridge Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $1,670,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Strategic Investment Solutions Inc. IL grew its holdings in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC grew its holdings in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new position in Novo Nordisk A/S during the first quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Transce3nd LLC acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of analyst reports. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Finally, Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Stock Up 1.3%

NVO traded up $0.94 during trading hours on Friday, hitting $71.67. 7,345,265 shares of the company's stock were exchanged, compared to its average volume of 7,144,964. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74. The stock's 50-day moving average is $70.67 and its two-hundred day moving average is $73.80. The stock has a market cap of $320.00 billion, a price-to-earnings ratio of 21.20, a PEG ratio of 1.36 and a beta of 0.64. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion during the quarter. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.